Ketamine for substance use disorders: a systematic review and meta-analysis
Frontiers in Psychiatry · 17.07.2026 · 17
DOI: 10.3389/fpsyt.2026.1835709 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Psychiatry, online erschienen am 17.07.2026. Verfasst von Shu-Ping Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Substance use disorder (SUD) is a major global health issue, contributing significantly to the disease burden. Despite this, effective treatments for SUD remain limited. Ketamine has shown potential as a treatment, yet no meta-analysis has assessed its efficacy for SUD. This study aimed to evaluate the efficacy and safety of ketamine in treating SUD.
Methods
Multiple databases were systematically searched forrandomized controlled trials (RCTs) on ketamine for SUD treatment. The primary outcome was abstinence rates. Adverse events and dropout rates were also assessed to evaluate safety and acceptability. A random-effects model was used to conduct the meta-analysis.
Results
Fifteen RCTs with 798 participants were included; seven RCTs contributed abstinence data to the quantitative synthesis. Ketamine was associated with significantly improved abstinence at <1 month [odds ratio(OR) = 3.27, 95% CI: 1.55–6.92, I 2 = 0%, p < 0.01], but not at 1–6 months (OR = 1.74, 95% CI: 0.91–3.30, I 2 = 0%, p = 0.09). No significant difference in dropout rates was observed between the ketamine and control groups (OR = 0.74, 95% CI: 0.46–1.21, I 2 = 0%, p = 0.23). No significant between group difference was identified in adverse events, although the available evidence was limited and insufficient to establish safety conclusively.
Discussion
Current evidence suggests a short-term efficacy signal for ketamine in SUD, but the evidence remains limited and insufficient to establish its efficacy and safety conclusively. Systematic review registration identifier CRD42024607116.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- National Center for Mental Disorders, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Social Psychiatry, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Radiology, Dazhou Hospital of Integrated Traditional Chinese and Western Medicine, Dazhou, China.
Zitieren
APA
Fang, S. P., Yang, X., Zhao, D. C., Wen, Y., Liu, Y. H., Li, Z., & Ran, M. S. (2026). Ketamine for substance use disorders: a systematic review and meta-analysis. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1835709
Vancouver
Fang SP, Yang X, Zhao DC, Wen Y, Liu YH, Li Z, et al. Ketamine for substance use disorders: a systematic review and meta-analysis. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1835709
BibTeX
@article{Fang2026,
author = {Fang, Shu-Ping and Yang, Xin and Zhao, Da-Cong and Wen, Yang and Liu, Yi-Hao and Li, Zhe and Ran, Mao-Sheng},
title = {Ketamine for substance use disorders: a systematic review and meta-analysis},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1835709}
}
EUVIMED